Trial Profile
A multicenter, randomized, double-blind study to determine the efficacy and safety of the addition of SYR-322 25 mg versus dose titration from 30 mg to 45 mg of pioglitazone HCl (ACTOS) in subjects with type 2 diabetes mellitus who have inadequate control on a combination of metformin and 30 mg of pioglitazone HCl therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 28 Jun 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 01 Dec 2011 Results published in the Diabetes, Obesity and Metabolism.
- 20 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD 2010).